Expansion of regulatory T cells via IL-2/anti-IL-2 mAb complexes suppresses experimental myasthenia

✍ Scribed by Ruolan Liu; Qinghua Zhou; Antonio La Cava; Denise I. Campagnolo; Luc Van Kaer; Fu-Dong Shi

• Publisher: John Wiley and Sons
• Year: 2010
• Tongue: English
• Weight: 635 KB
• Volume: 40
• Category: Article
• ISSN: 0014-2980
• DOI: 10.1002/eji.200939792

✦ Synopsis

Abstract

Human autoimmune diseases are often characterized by a relative deficiency in CD4^+^CD25^+^ regulatory T cells (Treg). We therefore hypothesized that expansion of Treg can ameliorate autoimmune pathology. We tested this hypothesis in an experimental model for autoimmune myasthenia gravis (MG), a B‐cell‐mediated disease characterized by auto‐Ab directed against the acetylcholine receptor within neuromuscular junctions. We showed that injection of immune complexes composed of the cytokine IL‐2 and anti‐IL‐2 mAb (JES6‐1A12) induced an effective and sustained expansion of Treg, via peripheral proliferation of CD4^+^CD25^+^Foxp3^+^ cells and peripheral conversion of CD4^+^CD25^−^Foxp3^−^ cells. The expanded Treg potently suppressed autoreactive T‐ and B‐cell responses to acetylcholine receptor and attenuated the muscular weakness that is characteristic of MG. Thus, IL‐2/anti‐IL‐2 mAb complexes can expand functional Treg in vivo, providing a potential clinical application of this modality for treatment of MG and other autoimmune disorders.